简介
谢方云教授 主任医师，愽士生导师。擅长头颈部肿瘤放射治疗，特别是鼻咽癌的精确调强放疗和综合治疗。曾主持和参与国家自然科学基金重点项目、国家自然科学基金面上项目,卫生部临床学科重点项目,广东省科技计划项目多个，参与项目的研究成果荣获2014年广东省科学技术一等奖、中华医学科技一等奖及国家科技进步二等奖。担任Br J Cancer,Cancer Epidemiol Biomarkers Pre,Tumor Biol,Radiat Oncol,Oral Oncol 等,杂志审稿人。主要研究鼻咽癌综合治疗方案、肿瘤分期及预后因素，近年以第一作者或通讯作者在Ann Oncol,Br J Cancer,J Biol Chem,Lancet Oncol,NEJM 等肿瘤学期刊发表论文30余篇，其临床研究成果得到美国癌症研究协会（AACR）网站新闻报道。主要科研项目： 1)中山大学临床医学研究5010计划项目，调强放疗加或不加同期化疗治疗低危鼻咽癌的III期非劣效性、随机对照、多中心研究，经费200万，2015-2025，第一负责人； 2)国家自然科学基金重点项目，cdh1(FZR1)磷酸化新点被调控的机理，对功能的影响及其 意义，经费174万，2009-2013，第二负责人； 3)中山大学临床医学研究5010计划，局部区域晚期鼻咽癌吉西他滨及顺铂诱导化疗联合同期放化疗对比同期放化疗的前瞻性多中心III期临床研究，经费200万， 2014-2023，第三负责人； 4)卫生部临床学科重点项目，基于调强放射疗的鼻咽癌预后模型及TPF诱导化疗的前瞻性研究，经费200万，2010-2013，第三负责人； 5）国家自然科学基金委员会，Fli-1靶向上调VEGF-C促进鼻咽癌转移的分子机制和临床意义研究，经费52万，2017-2020，第一负责人； 6）广东省自然科学基金管理委员会，Fli-1靶向调控VEGF-C促进鼻咽癌生长和转移的研究，经费10万，2017-2020，第一负责人； 7）广东省科学技术厅，多西他赛加顺铂（TP）对比单药顺铂（DDP）的同期化疗联合调强放疗治疗高危局部区域晚期鼻咽癌的随机对照II期临床研究；经费10万，2016-2018，第一负责人。 获奖: 参与研究项目获2014年广东省科学技术一等奖、中华医学科技一等奖及国家科技进步二等奖。第一作者及通讯作者论文第一及或通讯作者发表SCI文章1. Xiang-Bo Wan, Rou Jiang, Fang-Yun Xie (Co-first authors), Zhen-Yu Qi, Ai-Ju Li, Wei-Jun Ye, Yi-Jun Hua, Yu-Liang Zhu, Xiong Zou, Ling Gao, Hai-Qiang Mai, Xiang Guo, Ming-Huang Hong, Ming Yuan Che. Endoscope—guided interstitial intensity-modulated brachytherapy and intracavitary brachytherapy as boost radiation for primary early T stage nasopharyngeal carcinoma. PLoS One 2014;9;e90048.(IF 2.806)2. Xiao-Bin Lv, Fangyun Xie (Co-first authors), Kaishun Hu, Yuanzhong Wu, Lin-Lin Cao, Xia Han, Yi Sang, Yi-Xin Zeng, and Tiebang Kang. Damaged DNA-binding protein 1(DDB1) interacts with Cdhl and modulates the function of APC/CCdhl. J Biol Chem 2010; 285:18234-18240.（IF 4.125）3. Pu-Yun OuYang, MD, Lu-Ning Zhang, MD, Jie Tang, MD, Xiao-Wen Lan, MD, Yao Xiao, MD, Yuan-Hong Gao, MD, and Fang-Yun Xie, Md. Evaluation of Body Mass Index and Survival of Nasopharyngeal Carcinoma by Propensity-Matched Analysis: An Observational Case-Control Study. Medicine (Baltimore)2016;95:e2380(IF 1.803)4. Lu-Ning Zhang, Yuan-Hong Gao, Xiao-Wen Lan, Jie Tang, Zhen Su, Jun Ma, Wuguo Deng,Pu-Yun OuYang, Fang-Yun Xie. Propensity score matching analysis of cisplatin-based concurrent chemotheraoy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotheraphy era. Oncotarget 2015;6:44019-44029(IF 5.168) 5. P-Y OuYang, L-N Zhang, X-W Lan, C Xie, W-W Zhang, Q-X Wang, Z Su, J Tang and F-Y Xie. The significant survival advantage of female sex in nasopharyngeal carcinoma:a propensity-matched analysis. Br J Cancer 2015;112:1554-1561(IF 6.176)6. Lu-Ning Zhang, Jie Tang, Xiao-Wen Lan, Pu-Yun OuYang, Fang-Yun Xie. Pretreatment anemia and survival in nasopharyngeal carcinoma. Tumour Biol 2015(IF 3.65)7. Zhen Su, Yan-Ping Mao, Jie Tang, Xiao-Wen Lan, Pu-Yun Ouyang, Fang-Yun Xie. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT:a retrospective study. Tumour Biol 2015(IF 3.65)8. Lu-Ning Zhang, Yuan-Hong Gao, Xiao-Wen Lan, Jie Tang, Pu-Yun OuYang, Fang-Yun Xie. Effect of taxanes-based induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A large scale propensity-matched study. Oral Oncol 2015;51:950-956(IF 4.794)9. Zhen Su, Yan-Ping Mao, Pu-Yun OuYang, Jie Tang, Xiao-Wen Lan and Fang-Yun Xie. Leucopenia and treatment efficacy in advanced nasopharyngeal carcinoma. BMC Cancer 2015;15:429(IF 3.288)10. Zhen Su, Yan-Ping Mao, Pu-Yun OuYang, Jie Tang, Fang-Yun Xie. Initial Hyperleukocytosis and Neutrophilia in Nasopharyngeal Carcinoma: Incidence and Prognostic Impact. PLoS One2015;10:e0136752（IF 2.806）11. Xue-Xia Liang, Qun Li, Zhen Su, Xiao-Wen Lan, Pu-Yun OuYang, Yan-Ping Mao, Ding-Bo Shi, Wu-Guo Deng, Zhi-Bin Cheng, Si-Yang Wang, Fang-Yun Xie. Significant prognostic impact of chemoradiatherapy-induced hemoglobin decrease on treatment outcomes of nasopharyngeal carcinoma. J Cancer 2015;6;:502-510(IF 2.916)12. Pu-Yun OuYang, Zhen Su, Jie Tang, Xiao-Wen Lan, Yan-Ping Mao,Wuguo Deng, Fang-Yun Xie. Diabetes,Prediabetes and the Survival of Nasopharyngeal Carcinoma:A Study of 5,860 Patients. PLoS One2014;9:e111073(IF 2.806)13. Xuexia Liang, Dingbo Shi, Jingping Yun, Yanping Mao,Puyun Ouyang, Zhen Su, Jia Fu, Jinghui Hou, Wuguo Deng and Fangyun Xie. Friend leukemia virus integration 1 expression has prognostic significance in nasopharyngeal carcinoma. Transl Oncol 2014;7:493-502(IF 3.025)14.P.Y.OuYang,C.Xie,Y.P.Mao,Y.Zhang,X.X.Liang,Z.Su,Q.Liu&F.Y.Xie. Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-analysis of published literature-based randomized, controlled trials. Ann Oncol 2013;24:2136-2146(IF 11.855)15. P-Y OuYang, Z Su, Y-P Mao, Q Liu and F-Y Xie. Prognostic value of ABO blood group in southern Chinese patients with established nasopharyngeal carcinoma. Br J Cancer 2013;109:2462-2466(IF 6.176)16. Pu-Yun OuYang, Zhen Su, Yan-Ping Mao, Xue-Xia Liang, Qing Liu, Wu-Guo Deng, and Fang-Yun Xie. Prognostic impact of family history in southern Chinese patients with undifferentiated nasopharyngeal carcinoma. Br J Cancer 2013;109:788-794(IF 6.176)17. P-Y OuYang, Z Su,X-H Ma, Y-P Mao, M-Z Liu and F-Y Xie. Comparison of TNM staging systems for nasopharyngeal carcinoma, and proposal of a new staging system. Br J Cancer 2013;109:2987-29979（IF 6.176）18. P-Y OuYang, Z Su, Y-P Mao, X-X Liang, Q Liu and F-Y Xie. Prognostic impact of cigarette smoking on the survival of patients with established nasopharyngeal carcinoma.Cancer Epidemiol Biomarkers Prev 2013;22:2285-2294(IF 6.176)19. Pu-Yun OuYang, Zhen Su, Yan-Ping Mao, Wuguo Deng, Fang-Yun Xie. Combination of EGFR-TKIs and Chemotherapy as First-Line Therapy for Advanced NSCLC:A Meta-Analysis. PLoS One2018;8:e79000(IF 2.806)20. Xin Wang, Yi Liang, Qiong Chen, Hui-Min Xu, Nan Ge,Rong-Zhen Luo, Jian-Yong Shao, Zhi-Wei He, Yi-Xin Zeng, Tiebang Kang, Jing-Ping Yun &Fangyun Xie. Prognostic significance of SOX2 exoression in nasopharyngeal carcinoma. Cancer Invest 2012;30:79-85(IF 2.007)21. Hui-Min Xu, Yi Liang, Qiong Chen, Qi-Nian Wu, Yun-Miao Guo, Guo-Ping Shen, Ru-Hua Zhang, Zhi-Wei He, Yi-Xin Zeng, Fang-Yun Xie, and Tie-Bang Kang. Correlation of Skp2 overexpression to prognosis of patients with nasopharyngeal carcinoma from South China. Chin J Cancer2011;30:204-212(IF 4.111)22. Pu-Yun OuYang, Dingbo Shi, Rui Sun, Yu-Jia Zhu, Yao Xiao,Lu-Ning Zhang, Xu-Hui Zhang, Ze-Ying Chen, Xiao-Wen Lan, Jie Tang, Yuan-Hong Gao, Jun Ma, Wuguo Deng, Fang-Yun Xie. Effect of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy alone in nasopharyngeal carcinoma. Oncotarget. 2016 Apr 4.(IF 5.168)23. Zhen Su, Yan-Ping Mao, Jie Tang, Xiao-Wen Lan, Pu-Yun OuYang, Fang-Yun Xie. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study. Tumor Biol. 2016 Apr;37(4):4429-38(IF 3.65)24. Pu-Yun OuYang, Zhuo-Fei Bi, Lu-Ning Zhang, Kai-Yun You, Yao Xiao, Xiao-Wen Lan, Jie Tang, Xi-Cheng Wang, Wuguo Deng and Fang-Yun Xie. Outcomes of Induction Chemotherapy Plus Intensity-Modulated Radiotherapy (IMRT) Versus IMRT Plus Concurrent Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Study. Transl Oncol. 2016; 9(4):329-335.(IF 3.025)25. Xiao-Wen Lan, Xue-Bin Zou, Yao Xiao, Jie Tang, Pu-Yun OuYang, Zhen Su, Fang-Yun Xie. Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage Iva-b Nasopharyngeal Carcinoma:Plos One.2016;11(8):e0160758.(IF 2.806)26. Lei Chen, Chao-Su Hu, Xiao-Zhong Chen, Guo-Qing Hu, Zhi-Bin Cheng, Yan Sun, Wei-Xiong Li, Yuan-Yuan Chen, Fang-Yun Xie, Shao-Bo Liang, Yong Chen, Ting-Ting Xu, Bin Li, Guo-Xian Long, Si-Yang Wang, Bao-Min Zheng, Ying Guo, Ying Sun, Yan-Ping Mao, Ling-Long Tang, Yu-Ming Chen, Meng-Zhong Liu, Jun Ma.Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomiased controlled trial. Lancet Oncol2012;13:163-71(IF 33.9)27. Ying Sun, Wen-Fei Li, Nian-Yong Chen, Ning Zhang, Guo-Qing Hu, Fang-Yun Xie (Co-first authors), Yan Sun, Xiao-Zhong Chen, Jin-Gao Li, Xiao-Dong Zhu. Chao-Su Hu, Xiang-Ying Xu, Yuan-Yuan Chen, Wei-Han Hu, Ling Guo, Hao-Yuan Mo, Lei Chen, Yan-Ping Mao, Rui-Sun, Ping Ai, Shao-Bo Liang, Guo-Xian Long, Bao-Min Zhang, Xing-Lai Feng, Xiao-Chang Gong, Ling Li, Chun-Ying Shen, Jian-Yu Xu, Ying Guo, Yu-Ming Chen, Dan Zhang, Li Lin, Ling-Long Tang, Meng-Zhong Liu, Jun Ma. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicenter, randomized controlled trial. Lancet Oncol 2016:1470-2045(IF 33.9)28. Xiao-Wen Lan, Yao Xiao, Xue-Bin Zou, Pu-Yun OuYang, Fang-Yun Xie. Outcomes of adding induction chemotherapy to concurrent chemoradiotherapy for stage T3N0-1 nasopharyngeal carcinoma: a propensity-matched study. OncoTargets and Therapy 2017:10 3853-3860(IF 2.3184)29. Pu-Yun OuYang, Yao Xiao, Kai-Yun You, Lu-Ning Zhang, Xiao-Wen Lan, Xiao-Min Zhang, Fang-Yun Xie. Validation and comparison of the 7th and 8th edition of AJCC staging systems for non-metastatic nasopharyngeal carcinoma, and proposed staging systems from Hong Kong, Guangzhou, and Guangxi. Oral Oncol 2017; 72: 65-72. (IF 4.794)30. Pu-Yun OuYang, Lu-Ning Zhang, Yao Xiao, Xiao-Wen Lan, Xiao-Min Zhang, Jun Ma, Fang-Yun Xie. Validation of published nomograms and accordingly individualized induction chemotherapy in nasopharyngeal carcinoma. Oral Oncol 2017;67:37-45.(IF 4.794)
擅长
擅长头颈部肿瘤放疗，特别是鼻咽癌精确调强放疗及综合治疗
